Lund Melanoma Study Group
51 – 60 of 226
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
The proportion cured of patients with resected stage ii–iii cutaneous melanoma in sweden
(
- Contribution to journal › Article
-
Mark
The Prognostic Impact of Intratumoral Aryl Hydrocarbon Receptor in Primary Breast Cancer Depends on the Type of Endocrine Therapy : A Population-Based Cohort Study
(
- Contribution to journal › Article
-
Mark
BRN2 is a non-canonical melanoma tumor-suppressor
(
- Contribution to journal › Article
-
Mark
Birth cohort-specific trends of sun-related behaviors among individuals from an international consortium of melanoma-prone families
(
- Contribution to journal › Article
-
Mark
Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma
(
- Contribution to journal › Article
-
Mark
Mendelian randomisation study of smoking exposure in relation to breast cancer risk
(
- Contribution to journal › Article
-
Mark
Pre- and Postoperative Circulating IGF-I, IGFBP-3, and IGFBP-7 Levels in Relation to Endocrine Treatment and Breast Cancer Recurrence : A Nested Case-Control Study
(
- Contribution to journal › Article
-
Mark
Trend shifts in age-specific incidence for in situ and invasive cutaneous melanoma in sweden
(
- Contribution to journal › Article
-
Mark
PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma
(
- Contribution to journal › Article
-
Mark
Prognostic impact of tumor-specific insulin-like growth factor binding protein 7 (IGFBP7) levels in breast cancer : A prospective cohort study
(
- Contribution to journal › Article